Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.58 SEK | -0.36% | -8.52% | -27.15% |
Apr. 29 | Ziccum AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Mar. 14 | Ziccum AB Inhalable mRNA/LNP Project Confirms Excellent Properties Obtained by LaminarPace | CI |
Sales 2022 | 17K 1.64K | Sales 2023 | 6.32M 608K | Capitalization | 106M 10.17M |
---|---|---|---|---|---|
Net income 2022 | -28M -2.69M | Net income 2023 | -21M -2.02M | EV / Sales 2022 | 748 x |
Net cash position 2022 | 21.52M 2.07M | Net cash position 2023 | 2.14M 206K | EV / Sales 2023 | 16.4 x |
P/E ratio 2022 |
-1.19
x | P/E ratio 2023 |
-4.94
x | Employees | 9 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 75.41% |
1 day | -0.36% | ||
1 week | -8.52% | ||
Current month | -2.11% | ||
1 month | -7.00% | ||
3 months | -18.90% | ||
6 months | -25.99% | ||
Current year | -27.15% |
Managers | Title | Age | Since |
---|---|---|---|
Ann Gidner
CEO | Chief Executive Officer | 58 | 22-05-08 |
Johny Humaloja
DFI | Director of Finance/CFO | 58 | 23-06-14 |
Chairman | 44 | 17-04-04 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 44 | 17-04-04 | |
Per Magnus Gerde
BRD | Director/Board Member | - | - |
Director/Board Member | 44 | 21-04-26 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-05 | 5.58 | -0.36% | 15,118 |
24-06-04 | 5.6 | -1.06% | 35,930 |
24-06-03 | 5.66 | -0.70% | 27,011 |
24-05-31 | 5.7 | -1.04% | 30,603 |
24-05-30 | 5.76 | -2.04% | 37,424 |
Delayed Quote Nasdaq Stockholm, June 05, 2024 at 11:22 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-27.15% | 8.25M | |
-0.28% | 90.59B | |
0.00% | 38.99B | |
-8.52% | 34.09B | |
+64.13% | 26.38B | |
-17.37% | 15.02B | |
-5.99% | 13.17B | |
-10.69% | 11.88B | |
-47.78% | 10.65B | |
+8.09% | 9.25B |
- Stock Market
- Equities
- ZICC Stock